BRIEF published on 09/23/2024 at 08:20, 1 month 28 days ago Tissue Regenix Group Achieves First Pre-Tax Profit Market Expansion Pre-tax Profit Tissue Regenix Soft Tissue Repair Bone Repair
BRIEF published on 09/23/2024 at 08:20, 1 month 28 days ago Tissue Regenix Group réalise son premier bénéfice avant impôts Bénéfice Avant Impôts Expansion Du Marché Tissu Regenix Réparation Des Tissus Mous Réparation Osseuse
PRESS RELEASE published on 09/23/2024 at 08:15, 1 month 28 days ago Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit Hardman & Co Research reports on Tissue Regenix (TRX) achieving maiden pre-tax profit. TRX focuses on soft tissue and bone repair technologies, showing strong growth and profitability Hardman & Co Research Pre-tax Profit Tissue Regenix Soft Tissue Repair Bone Repair
BRIEF published on 06/25/2024 at 10:48, 4 months 26 days ago Decline of UK Life Sciences Sector Raises Concerns Investment Tissue Regenix Institutional Support UK Life Sciences Healthcare Index
BRIEF published on 06/25/2024 at 10:48, 4 months 26 days ago Le déclin du secteur britannique des sciences de la vie suscite des inquiétudes Investissement Régénix Des Tissus Sciences De La Vie Au Royaume-Uni Indice De Santé Appui Institutionnel
PRESS RELEASE published on 06/25/2024 at 10:43, 4 months 26 days ago Hardman & Co Insight: Survival of the UK life sciences sector Hardman & Co Research presents insights on the survival of the UK life sciences sector, highlighting challenges and opportunities for institutional investors. Discover more in the full report Investment Opportunities Hardman & Co Research Institutional Investors UK Life Sciences Sector Healthcare Stocks
BRIEF published on 04/10/2024 at 08:20, 7 months 11 days ago Hardman & Co Research Highlights Tissue Regenix's Impressive Growth Streak EBITDA Growth Tissue Regenix DCELL® BioRinse®
BRIEF published on 04/10/2024 at 08:20, 7 months 11 days ago Hardman & Co Research met en évidence la séquence de croissance impressionnante de Tissue Regenix Croissance BAIIA DCELL® BioRinse® Régénix Des Tissus
PRESS RELEASE published on 04/10/2024 at 08:15, 7 months 11 days ago Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth Hardman & Co Research highlights Tissue Regenix (TRX) with six consecutive periods of >20% growth, backed by strong commercial partners and expansion plans Hardman & Co Research Growth Investments Tissue Regenix EBITDA-positive
PRESS RELEASE published on 09/18/2023 at 11:40, 1 year 2 months ago Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
Published on 11/21/2024 at 12:00, 34 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 34 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 4 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 31 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 34 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:15, 19 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 4 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 1 hour 33 minutes ago Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 06:58, 5 hours 36 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 36 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 36 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 27 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 14 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
